Comparative Pharmacology
Head-to-head clinical analysis: CISATRACURIUM BESYLATE versus TUBOCURARINE CHLORIDE.
Head-to-head clinical analysis: CISATRACURIUM BESYLATE versus TUBOCURARINE CHLORIDE.
CISATRACURIUM BESYLATE vs TUBOCURARINE CHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, blocking neurotransmission and causing muscle paralysis.
Competitive antagonist at nicotinic acetylcholine receptors (nAChRs) at the neuromuscular junction, blocking ACh binding and preventing depolarization, resulting in skeletal muscle paralysis.
Initial IV bolus: 0.15-0.2 mg/kg (2×ED95) for intubation; maintenance: 0.03 mg/kg as needed or continuous infusion at 1-2 mcg/kg/min adjusted to twitch response. Titrate to train-of-four count of 1-2 twitches.
0.1-0.2 mg/kg intravenous bolus for initial intubation; maintenance: 0.05-0.1 mg/kg every 20-40 minutes as needed for neuromuscular blockade.
None Documented
None Documented
Terminal elimination half-life is 22–29 minutes in patients with normal renal and hepatic function; prolonged to ~30–40 minutes in elderly or patients with renal impairment; independent of hepatic function.
Terminal elimination half-life: 1.3–2.9 hours in adults with normal renal function. In renal failure, half-life is prolonged (up to 6–10 hours). Clinically, this leads to prolonged neuromuscular blockade in patients with renal impairment.
Renal (77%) and fecal/biliary (23%); unchanged drug eliminated primarily via renal excretion; Hofmann elimination (non-enzymatic degradation) accounts for ~80% of clearance.
Primarily renal excretion (approximately 70-80% unchanged in urine via glomerular filtration). A minor fraction (10-20%) is excreted in bile into feces. Less than 1% is metabolized (deacetylation to less active desmethyl derivatives).
Category C
Category C
Neuromuscular Blocker (Nondepolarizing)
Neuromuscular Blocker (Nondepolarizing)